The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Phage Choice, Isolation, and Preparation for Phage Therapy
Abstract
Phage therapy is the use of bacteriophages--viruses that use bacteria as their host cells--as biocontrol agents of bacteria. Currently, phage therapy is garnering renewed interest as bacterial resistance to antibiotics becomes widespread. Historically, phage therapy was largely abandoned in the West in the 1940s due to the advent of chemical antibiotics, and the unreliability of phage-based treatments when compared to antibiotics. The choice of phage strain and the methods of phage preparation are now thought to have been critical to the success or failure of phage therapy trials. Insufficiently virulent phages, especially against actual target bacteria, allow bacteria to survive treatment while poorly prepared phage stocks, even if of sufficiently virulent phages, lack the numbers of viable phages required for adequate treatment. In this review we discuss the factors that determine the methods of isolation, analysis, and identification of phage species for phage therapy. We go on to discuss the various methods available for purifying phages as well as considerations of the degree of purification which is sufficient for various applications. Lastly, we review the current practices used to prepare commercial phage therapy products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lysogenic Conversion by a Filamentous Phage Encoding Cholera Toxin
Waldor, M. K., & Mekalanos, J. J. (1996) · Science · doi:10.1126/science.272.5270.1910 · Cited by 1,879
Ecology of prokaryotic viruses
Weinbauer, M. G. (2004) · FEMS Microbiology Reviews · doi:10.1016/j.femsre.2003.08.001 · Cited by 1,771
Yamamoto, K. R., Alberts, B. M., Benzinger, R., Lawhorne, L., & Treiber, G. (1970) · Virology · doi:10.1016/0042-6822(70)90218-7 · Cited by 1,565
Bacteriophage Host Range and Bacterial Resistance
Hyman, P., & Abedon, S. T. (2010) · Advances in Applied Microbiology · doi:10.1016/s0065-2164(10)70007-1 · Cited by 819
Self-citationDowd, S. E., Sun, Y., Secor, P. R., Rhoads, D. D., Wolcott, B. M., James, G. A., & Wolcott, R. D. (2008) · BMC Microbiology · doi:10.1186/1471-2180-8-43 · Cited by 784
Phage Therapy in Clinical Practice: Treatment of Human Infections
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725401 · Cited by 670
Long-circulating bacteriophage as antibacterial agents.
Merril, C. R., Biswas, B., Carlton, R., Jensen, N. C., Creed, G. J., Zullo, S., & Adhya, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3188 · Cited by 512
Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., Van Parys, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004944 · Cited by 511
Switches in Bacteriophage Lambda Development
Oppenheim, A. B., Kobiler, O., Stavans, J., Court, D. L., & Adhya, S. (2005) · Annual Review of Genetics · doi:10.1146/annurev.genet.39.073003.113656 · Cited by 495
Biswas, B., Adhya, S., Washart, P., Paul, B., Trostel, A. N., Powell, B., Carlton, R., & Merril, C. R. (2002) · Infection and Immunity · doi:10.1128/iai.70.1.204-210.2002 · Cited by 467
The prospect for bacteriophage therapy in Western medicine
Merril, C. R., Scholl, D., & Adhya, S. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1111 · Cited by 367
Bacteriophage for Biocontrol of Foodborne Pathogens: Calculations and Considerations
Hagens, S., & Loessner, M. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725429 · Cited by 366
Practical Methods for Determining Phage Growth Parameters
Hyman, P., & Abedon, S. T. (2009) · Methods in Molecular Biology · doi:10.1007/978-1-60327-164-6_18 · Cited by 327
Self-citationMolecular biology of bacterial viruses
Stent, G. S. (1963) · Medical Entomology and Zoology · Cited by 319
Bacteriophages show promise as antimicrobial agents
Alisky, J., Iczkowski, K., Rapoport, A., & Troitsky, N. (1998) · Journal of Infection · doi:10.1016/s0163-4453(98)92874-2 · Cited by 318
Phage-Mediated Intergeneric Transfer of Toxin Genes
Chen, J., & Novick, R. P. (2009) · Science · doi:10.1126/science.1164783 · Cited by 314
Experimental Phage Therapy against Staphylococcus aureus in Mice
Capparelli, R., Parlato, M., Borriello, G., Salvatore, P., & Iannelli, D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01513-06 · Cited by 300
Abedon, S., & Thomas-Abedon, C. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725410 · Cited by 284
Jensen, E. C., Schrader, H. S., Rieland, B., Thompson, T. L., Lee, K. W., Nickerson, K. W., & Kokjohn, T. A. (1998) · Applied and Environmental Microbiology · doi:10.1128/aem.64.2.575-580.1998 · Cited by 267
Matsuzaki, S., Yasuda, M., Nishikawa, H., Kuroda, M., Ujihara, T., Shuin, T., Shen, Y., Jin, Z., Fujimoto, S., Nasimuzzaman, M. D., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/374001 · Cited by 260
Hanlon, G. W., Denyer, S. P., Olliff, C. J., & Ibrahim, L. J. (2001) · Applied and Environmental Microbiology · doi:10.1128/aem.67.6.2746-2753.2001 · Cited by 244
Markoishvili, K., Tsitlanadze, G., Katsarava, R., Glenn, J., Morris Jr., M. D., & Sulakvelidze, A. (2002) · International Journal of Dermatology · doi:10.1046/j.1365-4362.2002.01451.x · Cited by 243
Phage Therapy for Plant Disease Control
Balogh, B., Jones, J., Iriarte, F., & Momol, M. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725302 · Cited by 220
Modeling the role of bacteriophage in the control of cholera outbreaks
Jensen, M. A., Faruque, S. M., Mekalanos, J. J., & Levin, B. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600166103 · Cited by 213
Gill, J. J., Pacan, J. C., Carson, M. E., Leslie, K. E., Griffiths, M. W., & Sabour, P. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01630-05 · Cited by 185
Self-citationPhage Therapy of Local and Systemic Disease Caused by Vibrio vulnificus in Iron-Dextran-Treated Mice
Cerveny, K. E., DePaola, A., Duckworth, D. H., & Gulig, P. A. (2002) · Infection and Immunity · doi:10.1128/iai.70.11.6251-6262.2002 · Cited by 179
Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs
Johnson, R. P., Gyles, C. L., Huff, W. E., Ojha, S., Huff, G. R., Rath, N. C., & Donoghue, A. M. (2008) · Animal Health Research Reviews · doi:10.1017/s1466252308001576 · Cited by 161
Goodridge, L. D. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725348 · Cited by 155
Lytic infection ofEscherichia colibiofilms by bacteriophage T4
Doolittle, M. M., Cooney, J. J., & Caldwell, D. E. (1995) · Canadian Journal of Microbiology · doi:10.1139/m95-002 · Cited by 138
Félix d`Herelle and the Origins of Molecular Biology
Summers, W. C. (1999) · Cited by 138
Phage Production and Maintenance of Stocks, Including Expected Stock Lifetimes
Fortier, L., & Moineau, S. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-164-6_19 · Cited by 109
Preparation of endotoxin-free bacteriophages.
Boratyński, J., Syper, D., Weber‐Dąbrowska, B., Łusiak-Szelachowska, M., Poźniak, G., & Górski, A. (2004) · PubMed · Cited by 99
Effects of bacteriophages on free radical production and phagocytic functions
Przerwa, A., Zimecki, M., Świtała-Jeleń, K., Dąbrowska, K., Krawczyk, E., Łuczak, M., Weber‐Dąbrowska, B., Syper, D., Międzybrodzki, R., & Górski, A. (2006) · Medical Microbiology and Immunology · doi:10.1007/s00430-006-0011-4 · Cited by 92
Bacteriophage Therapy for Bacterial Infections: Rekindling a Memory from the Pre-Antibiotics Era
Ho, K. J. (2001) · Perspectives in biology and medicine · doi:10.1353/pbm.2001.0006 · Cited by 83
Callaway, T. R., Edrington, T. S., Brabban, A. D., Keen, J. E., Anderson, R. C., Rossman, M. L., Engler, M. J., Genovese, K. J., Gwartney, B. L., Reagan, J. O., et al. (2006) · Foodborne Pathogens and Disease · doi:10.1089/fpd.2006.3.234 · Cited by 82
Moradpour, Z., Sepehrizadeh, Z., Rahbarizadeh, F., Ghasemian, A., Yazdi, M. T., & Shahverdi, A. R. (2009) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2009.01620.x · Cited by 47
Cited by
Pros and cons of phage therapy
Loc-Carrillo, C., & Abedon, S. T. (2011) · Bacteriophage · doi:10.4161/bact.1.2.14590 · Cited by 1,020
Phage treatment of human infections
Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011) · Bacteriophage · doi:10.4161/bact.1.2.15845 · Cited by 980
Phage Cocktails and the Future of Phage Therapy
Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013) · Future Microbiology · doi:10.2217/fmb.13.47 · Cited by 914
Bacteriophage Host Range and Bacterial Resistance
Hyman, P., & Abedon, S. T. (2010) · Advances in Applied Microbiology · doi:10.1016/s0065-2164(10)70007-1 · Cited by 819
Self-citationPhage Therapy in Clinical Practice: Treatment of Human Infections
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725401 · Cited by 670
Metadata
- Authors
- Gill, J., & Hyman, P.
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 2-14
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2024931582
- Cited by
- 441
- References
- 36
- FWCI
- 13.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.